Inhibition of epstein-barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane

Molecular Carcinogenesis

Volumn 52, Issue 12, 2013, Pages 946-958

  Wu, Chung Chun ^a   Chuang, Hsin Ying ^a   Lin, Chao Yi ^a   Chen, Yen Ju ^b   Tsai, Wan Hua ^a   Fang, Chih Yeu ^a   Huang, Sheng Yen ^c   Chuang, Fu Yang ^a   Lin, Su Fang ^a   Chang, Yao ^a   Chen, Jen Yang ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Epstein Barr virus; Histone deacetylase inhibitor; Lytic cycle; Reactivation; Sulforaphane

Indexed keywords

SULFORAPHANE;

ANTIVIRAL ACTIVITY; ARTICLE; CARCINOMA CELL; CELL SPECIFICITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; EPITHELIUM CELL; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSACTIVATION; VIRUS REACTIVATION; WESTERN BLOTTING;

EPSTEIN-BARR VIRUS; HISTONE DEACETYLASE INHIBITOR; LYTIC CYCLE; REACTIVATION; SULFORAPHANE;

ANTIVIRAL AGENTS; DIETARY SUPPLEMENTS; EPITHELIAL CELLS; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, VIRAL; GENES, IMMEDIATE-EARLY; HERPESVIRUS 4, HUMAN; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMEDIATE-EARLY PROTEINS; ISOTHIOCYANATES; NASOPHARYNGEAL NEOPLASMS; PROMOTER REGIONS, GENETIC; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; VIRUS ACTIVATION;

HUMAN HERPESVIRUS 4;

EID: 84888065745     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21926     Document Type: Article

References (56)

1. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 2575-2627.
2. Fixman ED, Hayward GS, Hayward SD. Trans-acting requirements for replication of Epstein-Barr virus ori-Lyt. J Virol 1992; 66:5030-5039.
3. Feederle R, Kost M, Baumann M, et al. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 2000; 19:3080-3089.
4. Chang Y, Chang SS, Lee HH, Doong SL, Takada K, Tsai CH. Inhibition of the Epstein-Barr virus lytic cycle by Zta-targeted RNA interference. J Gen Virol 2004; 85:1371-1379.
5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
6. Ho JH. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978; 4:182-198.
7. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16:1310-1317.
8. Lin JC, Jan JS, Hsu CY, Jiang RS, Wang WY. Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: High complete response and low toxicity rates. Br J Cancer 2003; 88:187-194.
9. Triantos D, Porter SR, Scully C, Teo CG. Oral hairy leukoplakia: Clinicopathologic features, pathogenesis, diagnosis, and clinical significance. Clin Infect Dis 1997; 25:1392-1396.
10. Fang CY, Lee CH, Wu CC, et al. Recurrent chemical reactivations of EBV promotes genome instability and enhances tumor progression of nasopharyngeal carcinoma cells. Int J Cancer 2009; 124:2016-2025.
11. Ernberg I, Andersson J. Acyclovir efficiently inhibits oropharyngeal excretion of Epstein-Barr virus in patients with acute infectious mononucleosis. J Gen Virol 1986; 67:2267-2272.
12. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5:2894-2900.
13. Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol 2005; 79:13993-14003.
14. Chang LK, Wei TT, Chiu YF, et al. Inhibition of Epstein-Barr virus lytic cycle by (-)-epigallocatechin gallate. Biochem Biophys Res Commun 2003; 301:1062-1068.
15. Liu MY, Chen JY, Tsai CH, Hsu TY, Yang CS. Inhibition of the synthesis of proteins needed for Epstein-Barr virus replication by antisense RNA against the Zta gene. J Biomed Sci 1997; 4:139-145.
16. Lin JC, Nelson DJ, Lambe CU, Choi EI. Metabolic activation of 9([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human lymphoblastoid cell lines infected with Epstein-Barr virus. J Virol 1986; 60:569-573.
17. Andersson J, Britton S, Ernberg I, et al. Effect of acyclovir on infectious mononucleosis: A double-blind, placebo-controlled study. J Infect Dis 1986; 153:283-290.
18. Wang FZ, Roy D, Gershburg E, Whitehurst CB, Dittmer DP, Pagano JS. Maribavir inhibits Epstein-Barr virus transcription in addition to viral DNA replication. J Virol 2009; 83:12108-12117.
19. Sista ND, Pagano JS, Liao W, Kenney S. Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proc Natl Acad Sci USA 1993; 90:3894-3898.
20. Hergenhahn M, Soto U, Weninger A, et al. The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells. Mol Carcinog 2002; 33:137-145.
21. Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood) 2007; 232:227-234.
22. Countryman JK, Gradoville L, Miller G. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors. J Virol 2008; 82:4706-4719.
23. Tsai CH, Williams MV, Glaser R. Characterization of two monoclonal antibodies to Epstein-Barr virus diffuse early antigen which react to two different epitopes and have different biological function. J Virol Methods 1991; 33:47-52.
24. Tsai CH, Liu MT, Chen MR, et al. Characterization of monoclonal antibodies to the Zta and DNase proteins of Epstein-Barr virus. J Biomed Sci 1997; 4:69-77.
25. Lin CT, Wong CI, Chan WY, et al. Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab Invest J Tech Methods Pathol 1990; 62:713-724.
26. Glaser R, Zhang HY, Yao KT, et al. Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci USA 1989; 86:9524-9528.
27. Chang Y, Tung CH, Huang YT, Lu J, Chen JY, Tsai CH. Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes. J Virol 1999; 73:8857-8866.
28. Pulvertaft JV. Cytology of Burkitt's tumour (African lymphoma). Lancet 1964; 1:238-240.
29. Hinuma Y, Grace JT, Jr. Cloning of immunoglobulin-producing human leukemic and lymphoma cells in long-term cultures. Proc Soc Exp Biol Med Soc Exp Biol Med New York NY 1967; 124:107-111.
30. Pritchett R, Pedersen M, Kieff E. Complexity of EBV homologous DNA in continuous lymphoblastoid cell lines. Virology 1976; 74:227-231.
31. Huang SY, Fang CY, Tsai CH, et al. N-methyl-N'-nitro-N-nitrosoguanidine induces and cooperates with 12-O-tetradecanoylphorbol-1, 3-acetate/sodium butyrate to enhance Epstein-Barr virus reactivation and genome instability in nasopharyngeal carcinoma cells. Chem Biol Interact 2010; 188:623-634.
32. Yang PW, Chang SS, Tsai CH, Chao YH, Chen MR. Effect of phosphorylation on the transactivation activity of Epstein-Barr virus BMRF1, a major target of the viral BGLF4 kinase. J Gen Virol 2008; 89:884-895.
33. Chen YJ, Tsai WH, Chen YL, et al. Epstein-Barr virus (EBV) Rta-mediated EBV and Kaposi's sarcoma-associated herpesvirus lytic reactivations in 293 cells. PLoS ONE 6:e17809.
34. Myzak MC, Karplus PA, Chung FL, Dashwood RH. A novel mechanism of chemoprotection by sulforaphane: Inhibition of histone deacetylase. Cancer Res 2004; 64:5767-5774.
35. Lieberman PM, Hardwick JM, Sample J, Hayward GS, Hayward SD. The Zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions. J Virol 1990; 64:1143-1155.
36. Gamet-Payrastre L, Li P, Lumeau S, et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 2000; 60:1426-1433.
37. Villa-Cruz V, Davila J, Viana MT, Vazquez-Duhalt R. Effect of broccoli (Brassica oleracea) and its phytochemical sulforaphane in balanced diets on the detoxification enzymes levels of tilapia (Oreochromis niloticus) exposed to a carcinogenic and mutagenic pollutant. Chemosphere 2009; 74:1145-1151.
38. Johansson NL, Pavia CS, Chiao JW. Growth inhibition of a spectrum of bacterial and fungal pathogens by sulforaphane, an isothiocyanate product found in broccoli and other cruciferous vegetables. Planta Med 2008; 74:747-750.
39. Traka MH, Spinks CA, Doleman JF, et al. The dietary isothiocyanate sulforaphane modulates gene expression and alternative gene splicing in a PTEN null preclinical murine model of prostate cancer. Mol Cancer 2010; 9:189.
40. Kim MJ, Kim SH, Lim SJ. Comparison of the apoptosis-inducing capability of sulforaphane analogues in human colon cancer cells. Anticancer Res 2010; 30:3611-3619.
41. Sharma R, Ellis B, Sharma A. Role of alpha class glutathione transferases (GSTs) in chemoprevention: GSTA1 and A4 overexpressing human leukemia (HL60) cells resist sulforaphane and curcumin induced toxicity. Phytother Res 2011; 25:563-568.
42. Sestili P, Paolillo M, Lenzi M, et al. Sulforaphane induces DNA single strand breaks in cultured human cells. Mutat Res 2010; 689:65-73.
43. Misiewicz I, Skupinska K, Kowalska E, Lubinski J, Kasprzycka-Guttman T. Sulforaphane-mediated induction of a phase 2 detoxifying enzyme NAD(P)H:quinone reductase and apoptosis in human lymphoblastoid cells. Acta Biochim Pol 2004; 51:711-721.
44. Pledgie-Tracy A, Sobolewski MD, Davidson NE. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther 2007; 6:1013-1021.
45. Kawada J, Zou P, Mazitschek R, Bradner JE, Cohen JI. Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis. J Biol Chem 2009; 284:17102-17109.
46. Hui KF, Chiang AK. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. Int J Cancer 2010; 126:2479-2489.
47. Jenkins PJ, Binne UK, Farrell PJ. Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol 2000; 74:710-720.
48. Daigle D, Gradoville L, Tuck D, et al. Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle. J Virol 85:5628-5643.
49. Svehlikova V, Wang S, Jakubikova J, Williamson G, Mithen R, Bao Y. Interactions between sulforaphane and apigenin in the induction of UGT1A1 and GSTA1 in CaCo-2 cells. Carcinogenesis 2004; 25:1629-1637.
50. Chang LK, Chung JY, Hong YR, Ichimura T, Nakao M, Liu ST. Activation of Sp1-mediated transcription by Rta of Epstein-Barr virus via an interaction with MCAF1. Nucleic Acids Res 2005; 33:6528-6539.
51. Datta AK, Colby BM, Shaw JE, Pagano JS. Acyclovir inhibition of Epstein-Barr virus replication. Proc Natl Acad Sci USA 1980; 77:5163-5166.
52. Hsu M, Wu SY, Chang SS, et al. Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells. J Virol 2008; 82:3679-3688.
53. Tsai SC, Lin SJ, Chen PW, et al. EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines. Blood 2009; 114:109-118.
54. Wang Q, Tsao SW, Ooka T, et al. Anti-apoptotic role of BARF1 in gastric cancer cells. Cancer Lett 2006; 238:90-103.
55. Fiorini S, Ooka T. Secretion of Epstein-Barr virus-encoded BARF1 oncoprotein from latently infected B cells. Virol J 2008; 5:70.
56. Wu CC, Liu MT, Chang YT, et al. Epstein-Barr virus DNase (BGLF5) induces genomic instability in human epithelial cells. Nucleic Acids Res 2010; 38:1932-1949.